Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,597 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Daily Monitoring Clear all
Recruiting Not applicable Interventional

Digital Wellness Nurse - FIT Families: Virtual Family Intervention for Adolescent Obesity

NCT07087808
View directory record Official record
Conditions
Obese Children and Adolescents
Interventions
Digital Wellness Nurse - FIT Families
Behavioral
Lead sponsor
Machine and Human Interaction
Industry
Eligibility
12 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment

NCT02967250
View directory record Official record
Conditions
Parkinson Disease
Interventions
ursodeoxycholic acid
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections

NCT03931408
View directory record Official record
Conditions
Neurogenic Bladder, Spinal Cord Injuries
Interventions
Gentamicin Sulfate, Placebo instillation (saline alone), No instillation
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 3 Interventional Results available

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT04620733
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo, Seladelpar 5 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
40
States / cities
Chandler, Arizona • Little Rock, Arkansas • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome

NCT03495674
View directory record Official record
Conditions
High-Frequency Microsatellite Instability, Mismatch Repair Gene Mutation, Mutation-Negative Lynch Syndrome, Mutation-Positive Lynch Syndrome
Interventions
Exercise Intervention, Informational Intervention, Monitoring Device, Questionnaire Administration
Behavioral · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified

NCT01507753
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Omega-3 Supplementation, Psychoeducational Psychotherapy (PEP), Placebo
Drug · Behavioral · Other
Lead sponsor
L. Eugene Arnold
Other
Eligibility
7 Years to 14 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 19, 2026, 4:21 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers

NCT02587442
View directory record Official record
Conditions
Acute Radiation Syndrome
Interventions
RadProtect®
Drug
Lead sponsor
Original BioMedicals Co. Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dapagliflozin in Acute Heart Failure

NCT04298229
View directory record Official record
Conditions
Heart Failure, Diabetes Mellitus, Type 2
Interventions
Dapagliflozin 10 MG, Protocolized Diuretic Therapy
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Jackson, Mississippi • Chapel Hill, North Carolina • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 2 Interventional

Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

NCT06775041
View directory record Official record
Conditions
Hutchinson-Gilford Progeria Syndrome
Interventions
Progerinin, Lonafarnib
Drug
Lead sponsor
PRG Science & Technology Co., Ltd.
Industry
Eligibility
1 Year and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Not listed Not applicable Interventional

Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG

NCT04117022
View directory record Official record
Conditions
Diabetes, Diabetic Retinopathy
Interventions
DVS supplementation
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Pomona, California • Tahlequah, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 19, 2026, 4:21 AM EDT
Recruiting Not applicable Interventional

A Novel mHealth Intervention to Improve Outcomes of Children With Medical Complexity

NCT06883045
View directory record Official record
Conditions
Children With Medical Complexity
Interventions
MyChildCMC app (an app designed to facilitate home monitoring of CMC's health status)
Other
Lead sponsor
University of Utah
Other
Eligibility
1 Year to 18 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Not listed Not applicable Interventional

Messaging Interventions to Reduce Alcohol Problems Project

NCT03695653
View directory record Official record
Conditions
Alcohol-Related Disorders, Alcohol Use Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse
Interventions
Drink Tracking (MA), Adaptive Tailored (TA), Tailored (TO)
Behavioral
Lead sponsor
Partnership to End Addiction
Other
Eligibility
21 Years to 75 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT03755713
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) Community Study

NCT02092727
View directory record Official record
Conditions
Kidney Disease
Interventions
Behavioral Interventions for Dialysis Facilities
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 69 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 19, 2026, 4:21 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

NCT04216342
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Fx-5A peptide complex
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

NCT03605927
View directory record Official record
Conditions
Graft-versus-host-disease, GVHD, GVHD, Acute
Interventions
BMS-986004, Sirolimus, Tacrolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Duarte, California • Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Early Phase 1 Interventional Results available

Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

NCT01313923
View directory record Official record
Conditions
Pemphigus
Interventions
Sirolimus (formerly known as Rapamycin)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Not applicable Interventional

Treatment of Depression Using a Mobile Application in the Dominican Republic

NCT04948996
View directory record Official record
Conditions
Depression Mild, Depression Moderate
Interventions
El Buen Consejo Móvil- Group (EBCM-G), El Buen Consejo Móvil- Individual (EBCM-I)
Behavioral
Lead sponsor
Northern Illinois University
Other
Eligibility
18 Years to 110 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
DeKalb, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Tissue Oxygenation Measurement Using Multimodal Devices

NCT05784103
View directory record Official record
Conditions
Oxygen Saturation
Interventions
Clarifi Modulum, Perimed PeriFlux 5000, Apple Watch Oxygen Sensor, Innovo iP 900AP
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 19, 2026, 4:21 AM EDT
Withdrawn Not applicable Interventional

Parental Adherence of a Mobile Application

NCT06672042
View directory record Official record
Conditions
Pediatrics, Medically Complex, Children With Medical Complexity (CMC), Nursing
Interventions
CHAMP App
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Phase 4 Interventional Results available

Varenicline For Nicotine Vaping Cessation In Non Smoker Vaper Adolescents

NCT04602494
View directory record Official record
Conditions
Vaping, Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 4 Interventional Results available

Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation

NCT03511560
View directory record Official record
Conditions
Renal Transplant Rejection, Kidney Transplant Failure and Rejection
Interventions
Tacrolimus Extended Release Oral Tablet, Tacrolimus
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents

NCT01118988
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS), Functional Abdominal Pain, Fibromyalgia, Complex Regional Pain Syndrome (CRPS), Myofacial Pain, Chronic Daily Headaches, Migraine Headaches, Chronic Pain
Interventions
Mentorship
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 4 Interventional

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

NCT01076842
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 19, 2026, 4:21 AM EDT